Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Boehringer Ingelheim
Colorcon
Johnson and Johnson
Harvard Business School

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

CHILDREN'S ALLEGRA ALLERGY Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Children's Allegra Allergy, and when can generic versions of Children's Allegra Allergy launch?

Children's Allegra Allergy is a drug marketed by Sanofi Aventis Us and is included in three NDAs. There are two patents protecting this drug.

This drug has sixty-two patent family members in thirty-nine countries.

The generic ingredient in CHILDREN'S ALLEGRA ALLERGY is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and two suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Children's Allegra Allergy

A generic version of CHILDREN'S ALLEGRA ALLERGY was approved as fexofenadine hydrochloride by TEVA on September 1st, 2005.

  Start Trial

Summary for CHILDREN'S ALLEGRA ALLERGY
Drug patent expirations by year for CHILDREN'S ALLEGRA ALLERGY
Paragraph IV (Patent) Challenges for CHILDREN'S ALLEGRA ALLERGY

US Patents and Regulatory Information for CHILDREN'S ALLEGRA ALLERGY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride SUSPENSION;ORAL 201373-001 Jan 24, 2011 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021909-002 Jan 24, 2011 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-005 Jan 24, 2011 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CHILDREN'S ALLEGRA ALLERGY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET;ORAL 020872-005 Jan 24, 2011   Start Trial   Start Trial
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021909-002 Jan 24, 2011   Start Trial   Start Trial
Sanofi Aventis Us CHILDREN'S ALLEGRA ALLERGY fexofenadine hydrochloride SUSPENSION;ORAL 201373-001 Jan 24, 2011   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Boehringer Ingelheim
Colorcon
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.